Ustekinumab treatment in a patient with psoriasis and systemic lupus erythematosus

It, Chyuan; Th, Tsai; Th, Chang; Wu, Chien-Sheng

doi:10.1177/0961203314561072

Cited by 12 publications

(10 citation statements)

References 10 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three case reports of successful use of Ustekinumab in cutaneous lupus erythematosus without systemic involvement suggest that Th-17/ IL-23 may be involved in the pathogenesis of CLE [9,10,16]. Unlike our patient who had ongoing active SLE manifestations (thrombocytopenia), Chyuan et al reported a case of well controlled SLE and biopsy proven lupus nephritis, that developed resistant psoriasis, wherein Ustekinumab was successfully used and tolerated well, indicating its role in SLE [17].…”

Section: Discussionmentioning

confidence: 57%

Successful use of Ustekinumab in a Patient with Psoriasis, Psoriatic Arthritis and Systemic Lupus Erythematosus: A Case report and Review of literature

Kugasia¹

2017

BJSTR

View full text Add to dashboard Cite

Studies have demonstrated the role of TH-17 pathway in the pathogenesis of Systemic Lupus Erythematosus (SLE). Ustekinumab, a monoclonal antibody, binds and inhibits p40 subunit of IL-12 and 23, leading to IL-17 blockage, causing inhibition of TH-17 signaling pathway. Ustekinumab has rarely been used in the treatment of SLE. Herein, we discuss a patient with long standing history of Psoriasis and Psoriatic Arthritis, which was successfully being managed with anti TNF therapy. He was later diagnosed to have concomitant SLE. His persistently active and aggressive psoriatic lesions, arthritis and thrombocytopenia posed an interesting therapeutic dilemma. Fortunately his psoriatic lesions, arthritis and thrombocytopenia responded well to ustekinumab. Methotrexate was added to his regimen after improvement and he remained in remission on this therapy. Further clinical studies are ongoing to investigate the role of TH-17 blocking agents in SLE.

show abstract

Section: Discussionmentioning

confidence: 57%

Successful use of Ustekinumab in a Patient with Psoriasis, Psoriatic Arthritis and Systemic Lupus Erythematosus: A Case report and Review of literature

Kugasia¹

2017

BJSTR

View full text Add to dashboard Cite

show abstract

“…IL-17 (produced by Th17 lymphocytes) is elevated in the skin of patients with DLE 55. The use of ustekinumab in DLE has anecdotal evidence in the literature, mainly clinical cases in patients with concomitant psoriasis 56–60. Our experience is based on a patient with facial refractory DLE previously treated with classic therapies and rituximab, who achieved good response with ustekinumab (45 mg/12 weeks), first associated with methotrexate and intralesional corticosteroids for 30 months and then in monotherapy 61.…”

Section: Methodsmentioning

confidence: 99%

<p>Current Insights Into The Management Of Discoid Lupus Erythematosus</p>

Company-Quiroga¹,

Alique-García²,

Romero‐Maté³

2019

CCID

View full text Add to dashboard Cite

Discoid lupus erythematosus is the most disfiguring and common presentation of chronic cutaneous lupus erythematosus. Although most patients will respond to lifestyle measures and topical treatment, a non-negligible number of patients will require systemic and physical therapy, either alone or in combination. We performed a review of the available evidence on the discoid lupus erythematosus treatment. Lifestyle measures and topical treatment (corticosteroids and topical calcineurin inhibitors) remain the therapeutic strategies with the highest evidence level. Within systemic treatment approaches, antimalarial drugs are still the first-line therapy, while other systemic and physical therapies have highly variable evidence. Hence, we propose a therapeutic algorithm based on the strength of recommendations of the different treatment modalities, focusing on the refractory disease.

show abstract

“…Two of the patients, both with SLE, had to stop ustekinumab, owing to adverse events (cellulitis and a flare of psoriatic arthritis); the remaining four had good results. Chuyan [10] describes another patient with coexistent SLE and psoriasis, treated with ustekinumab with good results. Winchester [11] reported another case of psoriasis and DLE, successfully treated with ustekinumab.…”

Section: Dermatology Online Journal || Case Presentationmentioning

confidence: 99%

Successful treatment of recalcitrant discoid lupus erythematosus with ustekinumab

Romero‐Maté¹,

García‐Donoso²,

Hernández‐Núñez³

et al. 2017

Dermatology Online Journal

View full text Add to dashboard Cite

show abstract

Ustekinumab treatment in a patient with psoriasis and systemic lupus erythematosus

Cited by 12 publications

References 10 publications

Successful use of Ustekinumab in a Patient with Psoriasis, Psoriatic Arthritis and Systemic Lupus Erythematosus: A Case report and Review of literature

Successful use of Ustekinumab in a Patient with Psoriasis, Psoriatic Arthritis and Systemic Lupus Erythematosus: A Case report and Review of literature

<p>Current Insights Into The Management Of Discoid Lupus Erythematosus</p>

Successful treatment of recalcitrant discoid lupus erythematosus with ustekinumab

Contact Info

Product

Resources

About